Drug Profile
DA 3131
Alternative Names: DA-3131Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Dong-A ST
- Developer Dong-A Socio Holdings; Dong-A ST
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Age-related macular degeneration
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in South Korea (Ophthalmic)
- 19 Jul 2021 Preclinical development is ongoing South Korea (Dong-A Socio Holdings pipeline, July 2021)
- 19 Jul 2021 DA 3131 is available for licensing as of 19 Jul 2021. http://en.donga.co.kr/Pass.da?viewPath=/b03/bioMedicine#